Condition
Oligometastatic Prostate Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 14 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
14 shownProstate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate CancerNCT07686016 · 2026-06-26
RECRUITINGComprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate CancerNCT07015138 · 2025-06-01
RECRUITINGGenomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)NCT06387056 · 2024-04-01
RECRUITINGLu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative RadiotherapyNCT05560659 · 2023-12-14
RECRUITINGMaximal Tumor Eradication for Oligometastatic Prostate CancerNCT06972511 · 2023-08-20
RECRUITINGAdenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerNCT05915442 · 2023-07-01
RECRUITING5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)NCT04610372 · 2021-07-12
RECRUITINGBest Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)NCT07782112 · 2026-11-01
NOT_YET_RECRUITINGRezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate CancerNCT07490210 · 2026-05-01
NOT_YET_RECRUITINGProstate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)NCT06060652 · 2023-05-11
UNKNOWNThe Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate CancerNCT04992026 · 2021-01-01
COMPLETEDRadioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsisNCT03940235 · 2019-10-01
UNKNOWNPhase II Study of SBRT as Treatment for Oligometastases in Prostate CancerNCT02192788 · 2014-08-01
COMPLETEDRadiotherapy for Oligometastatic Prostate CancerNCT01859221 · 2013-05-01
COMPLETEDCommon interventions
Androgen Deprivation Therapy (ADT)DRUG21.Abiraterone Acetate TabletsDRUG1177Lu-PSMADRUG1CisplatinDRUG1Definitive Prostate-Directed RadiotherapyRADIATION1DocetaxelDRUG1EnzalutamideDRUG1EtrumadenantDRUG1Goserelin Microspheres for InjectionDRUG1High dose rate brachytherapyRADIATION1Hypofractionated external beam radiotherapyRADIATION1Luteinizing Hormone-Releasing Hormone AnalogDRUG1Metastasis-directed radiotherapyRADIATION1Metastasis-Directed Stereotactic Body RadiotherapyRADIATION1neoadjuvant apatamide plus ADT + radical resection of prostate cancer + extended lymph node dissection + radiotherapy of metastasesCOMBINATION_PRODUCT1NTRTRADIATION1PamiparibDRUG1Pelvic Lymph Node IrradiationRADIATION1Permanent seed implantRADIATION1Prednisone Acetate TabletsDRUG1Prostate BrachytherapyRADIATION1QuemliclustatDRUG1Radical prostatectomyPROCEDURE1Radiotherapy for MDT ± WPRTRADIATION1RezvilutamideDRUG1
Leading sponsors
Affidea Nu-med Center of Oncological DIagnostics and Therapy
1
British Columbia Cancer Agency
1
Catherine Spina
1
Centro di Riferimento Oncologico - Aviano
1
Ente Ospedaliero Cantonale, Bellinzona
1
European Institute of Oncology
1
Fudan University
1
Grupo de Investigación Clínica en Oncología Radioterapia
1
Peking University First Hospital
1
Peter MacCallum Cancer Centre, Australia
1
RenJi Hospital
1
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
1
The First Affiliated Hospital of Xiamen University
1
University of Florida
1
Trial status mix
RECRUITING7
COMPLETED3
NOT_YET_RECRUITING2
UNKNOWN2
Phase mix
PHASE27
NA4
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.